Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents That Concern Prescribers and Patients: a Feasibility Study and Call for a Trial

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jun 27

PMID 24968324

Citations 1

Authors

Amit C Achhra

Mark A Boyd

Matthew G Law

Gail V Matthews

Anthony D Kelleher

David A Cooper

Affiliations

Soon will be listed here.

Abstract

Objectives: Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens.

Design: Observational.

Methods: We first calculated RATE-sparing options available to an average patient receiving RATE agents. We reviewed treatment history and all resistance assays from patients attending the St. Vincent's Hospital (Sydney) clinic and receiving ≥2 RATE agents (n = 120). A viable RATE-sparing regimen with 2 or 3 fully-active agents was constructed from the following six 'safer' agents: rilpivirine or etravirine; atazanavir; raltegravir; maraviroc; and lamivudine. Activity for each drug was predicted as 1 (full-activity), 0.5 or 0 (no activity) using the Stanford mutation database. The utility of maraviroc was calculated assuming both maraviroc activity and inactivity where unknown. The analysis was restricted to regimens for which supporting evidence was identified in the literature or conference proceedings. Finally, we calculated the proportion of patients in the nationally representative Australian HIV Observational Database (AHOD) cohort receiving ≥2 RATE agents (n = 1473) to measure the potential population-level uptake of RATE-sparing agents.

Results: Assuming full maraviroc activity, 117(97.5%) and 107(89.2%) individuals had at least one option with 2 or 3 active RATE-sparing agents, respectively. Assuming no maraviroc activity this decreased to 113(94.2%) and 104(86.7%), respectively. In AHOD, 837(56.8%) patients were receiving ≥2 RATE agents.

Conclusion: Feasible treatment switch options sparing RATE agents exist for the majority of patients. Understanding the pros and cons of switching stable patients onto new RATE-sparing regimens requires evidence derived from randomised controlled trials.

Citing Articles

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

Achhra A, Nugent M, Mocroft A, Ryom L, Wyatt C Curr HIV/AIDS Rep. 2016; 13(3):149-57.

PMID: 27130284 DOI: 10.1007/s11904-016-0315-y.

References

Cordery D, Hesse K, Amin J, Cooper D . Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther. 2010; 15(7):1035-8. DOI: 10.3851/IMP1647. View

Monteiro P, Perez I, Laguno M, Martinez-Rebollar M, Gonzalez-Cordon A, Lonca M . Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother. 2013; 69(3):742-8. DOI: 10.1093/jac/dkt406. View

Allavena C, Mounoury O, Rodallec A, Reliquet V, Billaud E, Raffi F . Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials. 2009; 10(5):337-40. DOI: 10.1310/hct1005-337. View

Achhra A, Boyd M . Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther. 2013; 10(1):33. PMC: 3874614. DOI: 10.1186/1742-6405-10-33. View

Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y . Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS. 2011; 25(18):2249-58. DOI: 10.1097/QAD.0b013e32834c4c06. View

Boyd M, Kumarasamy N, Moore C, Nwizu C, Losso M, Mohapi L . Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen.... Lancet. 2013; 381(9883):2091-9. DOI: 10.1016/S0140-6736(13)61164-2. View

Hill A, Sawyer W . Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009; 10(9):527-35. DOI: 10.1111/j.1468-1293.2009.00724.x. View

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L . Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011; 76(16):1403-9. DOI: 10.1212/WNL.0b013e31821670fb. View

Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F . Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr. 2011; 56(4):e113-5. DOI: 10.1097/QAI.0b013e31820a9ae4. View

10.

Taiwo B, Zheng L, Gallien S, Matining R, Kuritzkes D, Wilson C . Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011; 25(17):2113-22. PMC: 3515052. DOI: 10.1097/QAD.0b013e32834bbaa9. View

11.

Squires K, Young B, DeJesus E, Bellos N, Murphy D, Ward D . ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012; 13(5):233-44. DOI: 10.1310/hct1305-233. View

12.

Katlama C, Assoumou L, Valantin M, Soulie C, Duvivier C, Chablais L . Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother. 2014; 69(6):1648-52. DOI: 10.1093/jac/dkt536. View

13.

Kozal M, Lupo S, DeJesus E, Molina J, McDonald C, Raffi F . A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012; 13(3):119-30. DOI: 10.1310/hct1303-119. View

14.

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L . Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression.... J Antimicrob Chemother. 2013; 68(6):1364-72. DOI: 10.1093/jac/dkt007. View

15.

Jansen A, Colbers E, van der Ven A, Richter C, Rockstroh J, Wasmuth J . Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Med. 2013; 14(7):449-52. DOI: 10.1111/hiv.12029. View

16.

Imaz A, Villar del Saz S, Ribas M, Curran A, Caballero E, Falco V . Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52(3):382-6. DOI: 10.1097/QAI.0b013e3181b17f53. View

17.

. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med. 2002; 3(1):28-36. DOI: 10.1046/j.1464-2662.2001.00094.x. View

18.

Achenbach C, Darin K, Murphy R, Katlama C . Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol. 2011; 6(2):157-177. PMC: 3127229. DOI: 10.2217/fvl.10.89. View

19.

Calza L . Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012; 13(4):189-211. DOI: 10.1310/hct1304-189. View

20.

Imaz A, Llibre J, Mora M, Mateo G, Camacho A, Blanco J . Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. J Antimicrob Chemother. 2010; 66(2):358-62. DOI: 10.1093/jac/dkq432. View